Table 5.

Review of the literature of different prospective trials on radiotherapy for oligometastases of breast cancer.

Author	Primary	Design	Definition	n patients	Follow-up	OS	PFS	LC
Milano et al. (8)	Indifferent	Prospective	≤5 sites	121	2 years	50%	/	/
	Breast	Single arm		39	2 years	74%	52%	87%
					6 years	47%	36%	87%
Milano et al. (11)	Breast	Prospective	≤5 sites	48
		Single arm	BM	12	5 years	83%	/	/
					10 years	75%	/	/
			Non-BM		5 years	31%	/	/
					10 years	17%	/	/
Scorsetti et al. (17)	Breast	Prospective	≤ 3 sites	33	1 year	93%	48%	98%
			Liver/lung		2 years	66%	27%	90%
					3 years	/	/	90%
Scorsetti et al. (9)	Indifferent	Prospective	≤3 sites	61	3 years	33%	/	86.8%
	Breast	Phase II	Liver	11	5 years	20%	/	86.8%
		Single arm
Trovo et al. (10)	Breast	Prospective	≤5 sites	54	1 year	/	75%	/
		Phase II	SBRT or IMRT		2 years	95%	53%	97%

With OS, overall survival; PFS, progression-free survival; LC, local control; SBRT, stereotactic body radiotherapy; IMRT, intensity modulated radiotherapy; BM, bone metastasis.